OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Pharmacological Sciences is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Subscription and Copyright Information	791
Subscription and Copyright Information	510
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	354
Subscription and Copyright Information	204
Subscription and Copyright Information	195
Advisory Board and Contents	180
Subscription and Copyright Information	168
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	152
Muscarinic receptors: from clinic to bench to clinic	146
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	142
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	131
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	126
Structural asymmetry in FGF23 signaling	119
Targeting complement in neurodegeneration: challenges, risks, and strategies	114
Swinging the SWI/SNF complexes for cancer therapy	112
Compstatins: the dawn of clinical C3-targeted complement inhibition	109
Structural pharmacology and mechanisms of GLP-1R signaling	104
Peptides as a therapeutic strategy against Klebsiella pneumoniae	103
Direct in vivo CAR T cell engineering	96
Shearing of surface mucin saps tumor cell strength	96
Therapeutic inhibition of ferroptosis in neurodegenerative disease	96
Advisory Board and Contents	94
Advisory Board and Contents	85
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	84
Phenotypic approaches for CNS drugs	80

Nemolizumab (Nemluvio®) for prurigo nodularis	78
Emerging strategies for beta cell transplantation to treat diabetes	78
Ribosome-directed cancer therapies: the tip of the iceberg?	75
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	75
A smart hospital-driven approach to precision pharmacovigilance	70
HSV-1 as a gene delivery platform for cancer gene therapy	70
Advisory Board and Contents	68
A deep dive into degrader-induced protein-protein interfaces	67
Engineering ACE2 decoy receptors to combat viral escapability	66
Optogenetic engineering for precision cancer immunotherapy	66
Leveraging human microbiomes for disease prediction and treatment	66
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	65
A perspective on psychedelic teratogenicity: the utility of zebrafish models	63
siRNA drug Leqvio (inclisiran) to lower cholesterol	62
Genetically engineered loaded extracellular vesicles for drug delivery	61
Advisory Board and Contents	61
Suzetrigine for moderate to severe acute pain	60
Close to a year in TIPS’ saddle – I am optimistic	58
Subscription and Copyright Information	58
Thriving as members of under-represented groups in pharmacology-related careers	57
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	54
Emerging approaches to induce immune tolerance to therapeutic proteins	53
Piezo1: structural pharmacology and mechanotransduction mechanisms	50
The structure, function, and pharmacology of MRGPRs	50
Could dexmedetomidine be repurposed as a glymphatic enhancer?	49
Subscription and Copyright Information	49